Back to top
more

Ligand Pharmaceuticals (LGND)

(Delayed Data from NSDQ)

$71.00 USD

71.00
152,955

+1.11 (1.59%)

Updated Apr 24, 2024 04:00 PM ET

After-Market: $70.80 -0.20 (-0.28%) 5:04 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

1-Strong Buy of 5 1        

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value D Growth B Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 31% (78 out of 252)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Balance Sheet

Research for LGND

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

   

Fiscal Year End for Ligand Pharmaceuticals Incorporated falls in the month of December.

All items in Millions except Per Share data.

12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Assets          
Cash & Equivalents 170 212 341 411 1,070
Receivables 39 35 92 59 42
Notes Receivable 0 0 0 0 0
Inventories 24 13 27 26 7
Other Current Assets 4 3 5 4 5
Total Current Assets 237 264 465 501 1,124
Net Property & Equipment 16 12 21 14 7
Investments & Advances 48 0 0 0 0
Other Non-Current Assets 0 0 0 0 0
Deferred Charges 0 9 34 24 26
Intangibles 470 458 742 796 326
Deposits & Other Assets 6 5 3 4 2
Total Assets 787 763 1,298 1,362 1,495
Liabilities & Shareholders Equity 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Notes Payable 0 0 0 0 0
Accounts Payable 2 5 8 4 2
Current Portion Long-Term Debt 0 77 0 0 0
Current Portion Capital Leases 0 0 0 7 0
Accrued Expenses 12 16 18 19 10
Income Taxes Payable 0 0 0 0 0
Other Current Liabilities 1 0 14 69 5
Total Current Liabilities 17 99 42 100 17
Mortgages 0 0 0 0 0
Deferred Taxes/Income 33 31 59 65 33
Convertible Debt 0 0 321 442 639
Long-Term Debt 0 0 0 0 0
Non-Current Capital Leases 0 0 0 0 0
Other Non-Current Liabilities 31 25 39 40 29
Minority Interest (Liabilities) 0 0 0 0 0
Total Liabilities 86 165 476 653 728
Shareholders Equity 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Preferred Stock 0 0 0 0 0
Common Stock (Par) 0 0 0 0 0
Capital Surplus 199 148 373 318 367
Retained Earnings 503 451 449 392 400
Other Equity -1 -1 -1 -1 0
Treasury Stock 0 0 0 0 0
Total Shareholder's Equity 701 597 821 710 767
Total Liabilities & Shareholder's Equity 787 763 1,298 1,362 1,495
Total Common Equity 701 597 821 710 767
Shares Outstanding 17.30 16.80 16.70 16.00 17.50
Book Value Per Share 40.52 35.56 49.17 44.35 43.84

Fiscal Year End for Ligand Pharmaceuticals Incorporated falls in the month of December.

All items in Millions except Per Share data.

3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023
Assets          
Cash & Equivalents -99,999 170 191 219 283
Receivables NA 39 36 28 29
Notes Receivable NA 0 0 0 0
Inventories NA 24 25 27 14
Other Current Assets NA 4 2 3 2
Total Current Assets NA 237 254 277 328
Net Property & Equipment NA 16 16 11 12
Investments & Advances NA 48 47 0 0
Other Non-Current Assets NA 0 0 0 0
Deferred Charges NA 0 9 9 1
Intangibles NA 470 425 442 450
Deposits & Other Assets NA 6 8 5 5
Total Assets NA 787 769 758 811
Liabilities & Shareholders Equity 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023
Notes Payable NA 0 0 0 0
Accounts Payable NA 2 2 10 6
Current Portion Long-Term Debt NA 0 0 0 77
Current Portion Capital Leases NA 0 0 0 0
Accrued Expenses NA 12 11 7 15
Income Taxes Payable NA 0 1 11 0
Other Current Liabilities NA 1 1 0 0
Total Current Liabilities NA 17 16 29 99
Mortgages NA 0 0 0 0
Deferred Taxes/Income NA 33 33 28 30
Convertible Debt NA 0 0 0 0
Long-Term Debt NA 0 0 0 0
Non-Current Capital Leases NA 0 0 0 0
Other Non-Current Liabilities NA 47 25 25
Minority Interest (Liabilities) NA 0 0 0 0
Total Liabilities NA 86 101 93 165
Shareholders Equity 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023
Preferred Stock NA 0 0 0 0
Common Stock (Par) NA 0 0 0 0
Capital Surplus NA 199 184 171 154
Retained Earnings NA 503 485 495 493
Other Equity NA -1 -1 -1 -1
Treasury Stock NA 0 0 0 0
Total Shareholder's Equity NA 701 668 665 646
Total Liabilities & Shareholder's Equity NA 787 769 758 811
Total Common Equity 0 701 668 665 646
Shares Outstanding 17.70 17.30 17.30 17.20 17.10
Book Value Per Share 0.00 40.52 38.61 38.66 37.80